“Isolation and characterization of a novel hormone receptor positive mammary adenocarcinoma MCa-P1362 with stromal drivers of tumor growth, metastasis, and drug resistance”

Samir Jana, Wende Li, Pin‐Ji Lei, Zixiong Wang, Peigen Huang, Dennis JonesbioRxiv 2023 · DOI

TL;DR

Researchers have developed and characterized a new mouse model of hormone receptor-positive breast cancer, MCa-P1362, which spontaneously metastasizes and exhibits resistance to endocrine therapies. This model, comprising both cancer and stromal cells, offers a more realistic platform for studying tumor progression and developing new treatment strategies for this common and challenging cancer subtype.

What Problem Does This Paper Address?

Hormone receptor-positive (HR+) breast cancers, driven by estrogen and progesterone, are the most common type and initially respond well to endocrine therapies. However, a significant proportion of patients develop resistance, leading to recurrence and metastasis. Studying the mechanisms behind this resistance and developing new therapies is crucial, but current preclinical models often fall short. Many existing mouse models either don't accurately mimic the metastatic potential of human breast cancer or require artificial estrogen supplementation, which doesn't reflect the clinical reality of postmenopausal women with low estrogen levels. Furthermore, these models often lack the complex tumor-stromal interactions and immune microenvironment that are critical for tumor progression and drug resistance in humans. This paper addresses the need for a more comprehensive and clinically relevant preclinical model for HR+ breast cancer.

Methods

The researchers established and characterized a novel syngeneic mouse model, MCa-P1362, derived from a spontaneous mammary tumor. Key techniques included:

  • In vivo passaging and tumor induction: The original tumor was serially transplanted into mice to generate isografts and establish a cell line.
  • Histopathology: Hematoxylin and eosin staining was used to examine tumor tissue morphology and confirm adenocarcinoma features.
  • Western blotting and immunofluorescence: These techniques were used to assess the expression of hormone receptors (ERα, PR) and HER2 in cancer cells.
  • In vitro proliferation assays (MTT): Used to measure the effect of estrogen and tamoxifen on cancer cell growth.
  • In vivo tumor growth and metastasis studies: Tumor volume was measured, and metastasis to lymph nodes, lungs, and liver was assessed.
  • Cell sorting (FACS): Cancer cells (EpCAM+) and stromal cells (EpCAM-) were isolated for further analysis.
  • RNA sequencing (RNA-seq): Performed on sorted cell populations to understand gene expression differences and identify key pathways.
  • Gene Set Enrichment Analysis (GSEA): Used to identify enriched biological pathways in different cell populations.
  • Quantitative real-time PCR (qPCR): Validated gene expression changes identified by RNA-seq.
  • ALDEFLUOR assay: Used to identify cancer stem cells (CSCs) based on aldehyde dehydrogenase activity.
  • In vitro differentiation assays: Assessed the differentiation potential of mesenchymal cells.
  • Co-culture experiments: Investigated the interaction and protective effects of stromal cells on cancer cells treated with drugs.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • A Clinically Relevant Model: MCa-P1362 is a valuable model because it spontaneously metastasizes and doesn't require exogenous estrogen for progression, mirroring aspects of human breast cancer more closely than many existing models.
  • Tumor Heterogeneity is Key: The model is not just cancer cells; it's a complex mix of epithelial cancer cells (EpCAM+) and mesenchymal stromal cells (EpCAM-), including cancer-associated fibroblasts (CAFs) and cancer stem cells (CSCs).
  • Stromal Cells Drive Progression and Resistance: The mesenchymal (EpCAM-) cells, particularly CAFs, play a crucial role in promoting tumor growth, metastasis, and conferring resistance to endocrine therapy (tamoxifen) and chemotherapy (paclitaxel, cisplatin).
  • Crosstalk is Essential: Functional studies showed that the interaction between cancer and stromal cells is vital for tumor progression and drug resistance, highlighting the importance of studying the tumor microenvironment.
  • Cancer Stem Cells are Present and Functional: Both cancer cells and mesenchymal cells contain populations with stem cell characteristics, contributing to tumor formation and potentially therapeutic resistance.

Key Results

  • The MCa-P1362 model expresses ERα, PR, and HER2, classifying it as a luminal B subtype, common in patients with poor prognosis.
  • MCa-P1362 cells proliferate in response to estrogen but can also grow independently of it.
  • MCa-P1362 tumors spontaneously metastasize to lymph nodes, lungs, and liver in syngeneic mice.
  • RNA-seq revealed distinct transcriptional profiles for EpCAM+ (cancer) and EpCAM- (mesenchymal) cells, with epithelial development genes upregulated in cancer cells and extracellular matrix genes enriched in mesenchymal cells.
  • EpCAM- cells exhibited mesenchymal stem cell-like properties and could differentiate into adipocytes and osteoblasts.
  • Co-culturing cancer cells with mesenchymal cells significantly increased their viability and resistance to tamoxifen, paclitaxel, and cisplatin.
  • MCa-P1362 cancer cells showed a higher resistance to 4-OHT compared to MCF-7 cells.
  • Ovariectomy did not significantly alter the growth kinetics of MCa-P1362 tumors, further supporting their independence from exogenous estrogen.

Limitations and Future Work

  • Heterogeneity of CAFs: The study acknowledges that CAFs are heterogeneous, and the specific subsets within MCa-P1362 tumors were not deeply investigated. Future work could explore the specific functions of different CAF subsets.
  • Model Limitations: While MCa-P1362 overcomes some limitations of existing models, it may not fully capture the heterogeneity seen across all human breast cancer patients.
  • Future Directions: The authors suggest that the established MCa-P1362 model provides a valuable platform for mechanistic studies of both intrinsic cancer cell resistance and tumor microenvironment-mediated resistance to breast cancer therapies. Further research can leverage this model to identify new therapeutic targets and develop combination therapies.

Summary updated

Abstract

Abstract Preclinical models that display spontaneous metastasis are necessary to improve therapeutic options for hormone receptor positive breast cancers. In this study, we conducted a detailed cellular and molecular characterization of MCa-P1362, a novel syngeneic Balb/c mouse model of metastatic breast cancer. MCa-P1362 cancer cells expressed estrogen receptors (ER), progesterone receptors (PR), and HER-2 receptors. MCa-P1362 cells proliferate in vitro and in vivo in response to estrogen, yet do not depend on steroid hormones for tumor progression. Further characterization of MCa-P1362 tumor explants shows that they contain a mixture of epithelial cancer cells and stromal cells. Based on transcriptomic and functional analyses of cancer and stromal cells, stem cells are present in both populations. Functional studies demonstrate that crosstalk between cancer and stromal cells promotes tumor growth, metastasis, and drug resistance. MCa-P1362 may serve as a useful preclinical model to investigate the cellular and molecular basis of hormone receptor positive tumor progression and therapeutic resistance.
BibTeX
@misc{jana2023isolation,
  author = {Samir Jana and Wende Li and Pin‐Ji Lei and Zixiong Wang and Peigen Huang and Dennis Jones},
  title = {{“Isolation and characterization of a novel hormone receptor positive mammary adenocarcinoma MCa-P1362 with stromal drivers of tumor growth, metastasis, and drug resistance”}},
  year = {2023},
  doi = {10.1101/2023.06.02.543434},
  howpublished = {bioRxiv},
}
Figure